Wells Fargo & Company Day One Biopharmaceuticals, Inc. Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 56,479 shares of DAWN stock, worth $722,366. This represents 0.0% of its overall portfolio holdings.
Number of Shares
56,479
Previous 56,936
0.8%
Holding current value
$722,366
Previous $784,000
0.26%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding DAWN
# of Institutions
178Shares Held
84MCall Options Held
144KPut Options Held
218K-
Ra Capital Management, L.P. Boston, MA7.87MShares$101 Million1.53% of portfolio
-
Atlas Venture Life Science Advisors, LLC6.43MShares$82.2 Million11.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.89MShares$75.3 Million0.0% of portfolio
-
Braidwell LP Stamford, CT4.87MShares$62.3 Million1.92% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$58 Million0.0% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $940M
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...